Clene cut a six-week ALS data task to one week. Can faster analysis help its $9.9m cash runway?
Clene and Veristat cut ALS filing analysis time by 80%. See how automation, FDA requirements and financing affect CNM-Au8's regulatory outlook.
Medical Devices & Diagnostics
Pharma & Biotech
What Clene Inc.’s FDA feedback reveals about the future of surrogate endpoints in ALS trials
Can biomarker-driven approvals transform ALS drug development? Explore how Clene Inc.’s FDA feedback on CNM-Au8 could accelerate innovation.